Market Closed -
Nasdaq Stockholm
12:00:00 2024-07-12 pm EDT
|
5-day change
|
1st Jan Change
|
0.274
SEK
|
+2.05%
|
|
+1.48%
|
-32.76%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,835
|
1,856
|
1,847
|
1,176
|
233.5
|
219.3
|
Enterprise Value (EV)
1 |
2,006
|
1,880
|
1,651
|
1,089
|
99.17
|
142.2
|
P/E ratio
|
-12.9
x
|
-3.97
x
|
-8.78
x
|
-8.86
x
|
-0.6
x
|
-1.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
149
x
|
178
x
|
465
x
|
40.7
x
|
76.8
x
|
33.2
x
|
EV / Revenue
|
163
x
|
181
x
|
416
x
|
37.7
x
|
32.6
x
|
21.5
x
|
EV / EBITDA
|
-20
x
|
-15.5
x
|
-9.21
x
|
-8.81
x
|
-0.76
x
|
-1.75
x
|
EV / FCF
|
-13.4
x
|
-41.9
x
|
-35.8
x
|
-18.8
x
|
-2.46
x
|
24
x
|
FCF Yield
|
-7.46%
|
-2.39%
|
-2.79%
|
-5.31%
|
-40.7%
|
4.16%
|
Price to Book
|
4.68
x
|
2.37
x
|
2.72
x
|
2.14
x
|
0.72
x
|
1.11
x
|
Nbr of stocks (in thousands)
|
200,524
|
448,370
|
448,370
|
448,370
|
538,043
|
538,043
|
Reference price
2 |
9.150
|
4.140
|
4.120
|
2.623
|
0.4340
|
0.4075
|
Announcement Date
|
9/14/18
|
9/5/19
|
4/29/21
|
4/28/22
|
4/25/23
|
4/23/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
12.33
|
10.41
|
3.972
|
28.87
|
3.04
|
6.612
|
EBITDA
1 |
-100.4
|
-121.1
|
-179.3
|
-123.6
|
-130.1
|
-81.14
|
EBIT
1 |
-105.2
|
-126.3
|
-182.9
|
-128.8
|
-135
|
-86.09
|
Operating Margin
|
-853.33%
|
-1,213.43%
|
-4,605.32%
|
-446.32%
|
-4,441.38%
|
-1,302%
|
Earnings before Tax (EBT)
1 |
-118
|
-169.1
|
-210.4
|
-132.7
|
-356.7
|
-128.7
|
Net income
1 |
-118
|
-201.9
|
-210.4
|
-132.7
|
-356.7
|
-128.7
|
Net margin
|
-957.38%
|
-1,939.16%
|
-5,297.21%
|
-459.75%
|
-11,734.18%
|
-1,947.07%
|
EPS
2 |
-0.7100
|
-1.044
|
-0.4693
|
-0.2960
|
-0.7233
|
-0.2393
|
Free Cash Flow
1 |
-149.6
|
-44.88
|
-46.09
|
-57.85
|
-40.39
|
5.916
|
FCF margin
|
-1,213.97%
|
-431.1%
|
-1,160.35%
|
-200.4%
|
-1,328.68%
|
89.47%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/14/18
|
9/5/19
|
4/29/21
|
4/28/22
|
4/25/23
|
4/23/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
172
|
23.3
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
197
|
86.8
|
134
|
77
|
Leverage (Debt/EBITDA)
|
-1.71
x
|
-0.1923
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-150
|
-44.9
|
-46.1
|
-57.9
|
-40.4
|
5.92
|
ROE (net income / shareholders' equity)
|
-36.6%
|
-54.7%
|
-1.75%
|
-21.6%
|
-81.5%
|
-49.1%
|
ROA (Net income/ Total Assets)
|
-12.1%
|
-13.4%
|
-1.8%
|
-11%
|
-17.8%
|
-18.9%
|
Assets
1 |
978
|
1,512
|
11,660
|
1,201
|
2,008
|
680.9
|
Book Value Per Share
2 |
1.960
|
1.750
|
1.520
|
1.230
|
0.6000
|
0.3700
|
Cash Flow per Share
2 |
0.0900
|
0.5200
|
0.0900
|
0.0200
|
0.0200
|
0.0100
|
Capex
1 |
0.42
|
2.5
|
6.55
|
1.11
|
0.28
|
0.66
|
Capex / Sales
|
3.37%
|
23.97%
|
164.88%
|
3.86%
|
9.11%
|
9.97%
|
Announcement Date
|
9/14/18
|
9/5/19
|
4/29/21
|
4/28/22
|
4/25/23
|
4/23/24
|
|
1st Jan change
|
Capi.
|
---|
| -32.76% | 13.78M | | +62.79% | 841B | | +40.42% | 625B | | -3.99% | 360B | | +17.59% | 327B | | +9.88% | 300B | | +15.66% | 242B | | +17.90% | 227B | | +15.20% | 174B | | +0.78% | 162B |
Other Pharmaceuticals
|